Nick Leschly, bluebird bio CEO (Jeff Rumans)
February 23, 2021 05:34 PM ESTUpdated February 24, 07:13 AM
FDA+

It's of­fi­cial: FDA clamps a hold on blue­bird's trou­bled Lenti­Glo­bin pro­gram while EMA con­sid­ers new mea­sures

John Carroll

Editor & Founder

What start­ed out as a vol­un­tary hold of a crit­i­cal de­vel­op­ment pro­gram at blue­bird bio has gone in­to an of­fi­cial lock­up at the FDA. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times